NCT06947707

Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients

Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients: A Prospective Cohort Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,486 (estimated)
• Sponsor: Xuanwu Hospital, Beijing · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous thrombosis (CVT). The main question it aims to answer are: * Do cerebral veins or venous sinuses recanalize during the treatment period of edoxaban and rivaroxaban? * Do the bleeding events occur during the treatment period of edoxaban and rivaroxaban? The main tasks participants will be asked to do: * Participants will comply fully with the prescribed regimen and take the edoxaban or rivaroxaban as directed at the specified dosage. * Participants will return to hospital for scheduled follow-up assessments at months 3, 6, 9, and 12 post-enrollment to undergo face-to-face visits with investigators.

Conditions

• Cerebral Venous Thrombosis
• Anticoagulants and Thrombotic Disorders
• Anticoagulation Treatment
• Anticoagulant Therapy
• Anticoagulant Drugs
• NOACs
• Anticoagulant Prophylaxis/Therapy
• Anticoagulation With NOAC
• Anticoagulation With Direct Oral Anticoagulants

Timeline

• Start date: 2025-04-10
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2025-04-27
• Last updated: 2025-04-27

Locations

1 site across 1 country: China